Arkolith/Insider Trading/CNSP/Form 4

Downs Christopher

Chief Financial OfficerCNS Pharmaceuticals, Inc. (CNSP) · full profile →Form 4 · filed Feb 6, 2024
Net Buying
Open-Market Buys
$20K
Open-Market Sells
$0
Net Open-Market Flow
$20K
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2024Buy(P)67K$0.30$20K103K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)67K——95K
Feb 1, 2024Grant(A)67K——162K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001683168-24-000706) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML